Skip to main content
. 2022 Aug 6;14(8):1643. doi: 10.3390/pharmaceutics14081643

Table 2.

BBB designs factors and Observed responses for Qu-PMMs.

Run A B C Y1 Y2 Y3
1 20 0.5 0.3 187.700 ± 8.654 0.398 ± 0.057 79.800 ± 0.721
2 20 0.1 0.2 107.167 ± 1.069 0.236 ± 0.053 77.460 ± 1.945
3 15 0.5 0.2 228.400 ± 8.190 0.296 ± 0.055 57.000 ± 1.952
4 20 1.0 0.2 192.320 ± 5.155 0.269 ± 0.014 59.920 ± 2.316
5 15 1.0 0.3 385.030 ± 6.615 0.330 ± 0.025 80.370 ± 1.316
6 15 0.5 0.2 231.730 ± 5.139 0.283 ± 0.044 55.610 ± 1.561
7 10 1.0 0.2 184.100 ± 3.820 0.264 ± 0.020 60.620 ± 1.660
8 15 0.1 0.1 541.560 ± 0.252 0.803 ± 0.055 55.550 ± 0.547
9 20 0.5 0.1 158.730 ± 5.519 0.345 ± 0.019 43.670 ± 0.846
10 15 0.5 0.2 228.400 ± 8.190 0.289 ± 0.046 76.330 ± 1.030
11 15 0.1 0.3 194.500 ± 1.706 0.393 ± 0.020 64.260 ± 0.981
12 15 1.0 0.1 299.430 ± 5.123 0.648 ± 0.021 72.310 ± 0.993
13 10 0.5 0.1 294.500 ± 1.706 0.393 ± 0.020 41.980 ± 1.547
14 10 0.1 0.2 321.960 ± 0.252 0.364 ± 0.020 37.280 ± 3.268
15 10 0.5 0.3 441.560 ± 9.075 0.397 ± 0.043 43.670 ± 0.846
16 15 0.5 0.2 225.060 ± 10.696 0.273 ± 0.011 58.000 ± 2.157
17 15 0.5 0.2 226.730 ± 9.078 0.281 ± 0.020 57.330 ± 2.521

A = Soluplus (mg mL−1), B = E-TPGS (mg mL−1), C = poloxamer 407 (% w/v), Y1 = Particle size (nm), Y2 = PDI and Y3 = Entrapment Efficiency (%). Data are represented in means ± Standard deviation (n = 3).

HHS Vulnerability Disclosure